

# 1 **Oligomerisation-driven MLKL ubiquitylation antagonises necroptosis**

2  
3 Zikou Liu<sup>1,2</sup>, Laura F. Dagley<sup>1,2</sup>, Kristy Shield-Artin<sup>1,2</sup>, Samuel N. Young<sup>1</sup>, Aleksandra  
4 Bankovacki<sup>1,6</sup>, Xiangyi Wang<sup>1,2</sup>, Michelle Tang<sup>3,4</sup>, Jason Howitt<sup>3,4</sup>, Che A. Stafford<sup>5</sup>, Ueli  
5 Nachbur<sup>1,2</sup>, Cheree Fitzgibbon<sup>1</sup>, Sarah E. Garnish<sup>1,2</sup>, Andrew I. Webb<sup>1,2</sup>, David Komander<sup>1,2</sup>,  
6 James M. Murphy<sup>1,2</sup>, Joanne M. Hildebrand<sup>1,2^</sup>, John Silke<sup>1,2^</sup>

7  
8 <sup>1</sup> The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia

9 <sup>2</sup> Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia

10 <sup>3</sup> The Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3052, Australia

11 <sup>4</sup> Swinburne University of Technology, Hawthorn, VIC 3122, Australia

12 <sup>5</sup> Gene Centre and Department of Biochemistry, Ludwig Maximilian University of Munich,  
13 Munich 80331, Germany

14 <sup>6</sup> Translational Research, CSL Limited, Melbourne, VIC 3010, Australia

15 ^ Corresponding authors

16

## 17 **Running Title**

18 MLKL ubiquitylation during necroptosis

19

## 20 **Abstract**

21 Mixed lineage kinase domain-like (MLKL) is the executioner in the caspase-independent  
22 form of programmed cell death called necroptosis. Receptor-interacting serine/threonine  
23 protein kinase 3 (RIPK3) phosphorylates MLKL, triggering MLKL oligomerization,  
24 membrane translocation and membrane disruption. MLKL also undergoes ubiquitylation  
25 during necroptosis, yet neither the mechanism nor the significance of this event has been  
26 demonstrated. Here we show that necroptosis-specific multi-mono-ubiquitylation of MLKL  
27 occurs following its activation and oligomerization. Ubiquitylated MLKL accumulates in a  
28 digitonin-insoluble cell fraction comprising organellar and plasma membranes and protein  
29 aggregates. Appearance of this ubiquitylated MLKL form can be reduced by expression of a  
30 plasma membrane-located deubiquitylating enzyme. Oligomerization-induced MLKL  
31 ubiquitylation occurs on at least four separate lysine residues, and correlates with its  
**This is the author manuscript accepted for publication and has undergone full peer review but  
has not been through the copyediting, typesetting, pagination and proofreading process, which  
may lead to differences between this version and the [Version of Record](#). Please cite this article  
as [doi: 10.15252/EMBJ.2019103718](https://doi.org/10.15252/EMBJ.2019103718)**

This article is protected by copyright. All rights reserved

1 proteasome- and lysosome-dependent turnover. Using a MLKL-DUB fusion strategy, we  
2 show that constitutive removal of ubiquitin from MLKL licences MLKL auto-activation  
3 independent of necroptosis signalling in mouse and human cells. Therefore, in addition to the  
4 role of ubiquitylation in the kinetic regulation of MLKL-induced death following an  
5 exogenous necroptotic stimulus, it also contributes to restraining basal levels of activated  
6 MLKL to avoid unwanted cell death.

#### 8 **Key words**

9 Membranes/MLKL/necroptosis/DUB-fusion/ubiquitylation

## 11 **Introduction**

12 Necroptosis is a type of programmed cell death that shares some molecular components with  
13 the better-known apoptotic cell death pathway, but has distinct morphological features and  
14 different physiological consequences. Unlike apoptosis, which is immunologically silent and  
15 can be rapidly cleared by neighbouring phagocytic cells (Segawa and Nagata 2015),  
16 necroptosis induces an inflammatory response by releasing cellular contents including DNA  
17 and cytosolic proteins (Kaczmarek, Vandenberghe et al. 2013). Necroptosis can be induced  
18 by a number of stimuli, but is mainly studied downstream of Tumor Necrosis Factor (TNF)  
19 ligation to its receptor Tumor Necrosis Factor Receptor 1 (TNFR1). If Inhibitor of Apoptosis  
20 (IAP) proteins and caspase activities are suppressed, this results in higher order assemblies of  
21 Receptor Interacting serine/threonine Protein Kinase 1 (RIPK1) and RIPK3, and subsequent  
22 RIPK3 activation and auto-phosphorylation (Sun, Yin et al. 2002, Wu, Yang et al. 2014).  
23 MLKL is phosphorylated by RIPK3 and oligomerises, translocates to biological membranes  
24 and induces organelle and cell swelling and membrane rupture (Vandenberghe, Kaiser et al.  
25 2015, Petrie, Czabotar et al. 2019).

26  
27 Ubiquitylation plays a pivotal role in regulating TNF signalling. In addition to RIPK1  
28 ubiquitylation by cIAPs, which forms a platform for MAPK and NF- $\kappa$ B activation (Bertrand,  
29 Milutinovic et al. 2008), the Linear Ubiquitin Chain Assembly Complex (LUBAC),  
30 composed of HOIL-1, HOIP and SHARPIN, generates M1-linked ubiquitin chains on RIPK1,  
31 TRADD, TNFR1 and NEMO. This ubiquitylation leads to full activation of IKK and MAPK,  
32 and limits TNF induced cell death (Haas, Emmerich et al. 2009, Tokunaga, Sakata et al. 2009,  
33 Ikeda, Deribe et al. 2011). LUBAC also recruits CYLD, a deubiquitylating enzyme (DUB),

This article is protected by copyright. All rights reserved

1 that removes M1- and K63-linked ubiquitin chains on RIPK1 and other complex components,  
2 while A20 sterically protects M1-linked ubiquitin chains (Draber, Kupka et al. 2015,  
3 Dondelinger, Darding et al. 2016).

4  
5 Ubiquitylation has been implicated in the regulation of signalling checkpoints during  
6 necroptosis. RIPK3 undergoes K63-linked ubiquitylation on Lys-5, which is believed to  
7 support the formation of necrosome. Removal of this ubiquitin chain by the ubiquitin-editing  
8 enzyme A20 was proposed to negate necroptosis, because A20 loss led to RIPK3-dependent  
9 necroptosis in T cells and fibroblasts (Onizawa, Oshima et al. 2015). Furthermore,  
10 ubiquitylated TRAF2 was reported to be associated with inactive MLKL, and CYLD  
11 deubiquitylates TRAF2 following necroptotic stimulation, allowing TRAF2 to dissociate  
12 from MLKL and MLKL to engage with, and be activated by, RIPK3 (Petersen, Chen et al.  
13 2015).

14  
15 MLKL has also been shown to undergo ubiquitylation upon necroptotic stimulation (Lawlor,  
16 Khan et al. 2015, Hildebrand, Kauppi et al. 2020), yet the significance of this post-  
17 translational modification and its signalling function are unknown. Here we show that  
18 necroptotic signalling stimulates MLKL ubiquitylation and that this antagonises necroptosis  
19 *via* restraining the protein level of activated MLKL. MLKL oligomerization is the crucial  
20 stage for MLKL ubiquitylation, but RIPK3 phosphorylation is not necessary because auto-  
21 active oligomerizable MLKL mutants are ubiquitylated. MLKL ubiquitylation was removed  
22 *in vitro* by USP21, but not by other chain specific deubiquitylating enzymes, suggesting that  
23 MLKL is mono-ubiquitylated at multiples sites. Upon necroptotic stimulation, MLKL  
24 variants that are unable to induce cell death can still be ubiquitylated and this correlates with  
25 proteasome/lysosome mediated turnover. Conversely, mutation of four lysine residues  
26 identified by mass spectrometry analysis to be ubiquitylated following a necroptotic stimulus  
27 did not affect MLKL ubiquitylation or MLKL's cytotoxic activity. We therefore devised a  
28 novel approach to completely remove all ubiquitins from MLKL by fusing it to USP21. We  
29 showed that this MLKL-USP21 fusion was resistant to ubiquitylation in both human and  
30 mouse cell lines and was more cytotoxic when compared with MLKL fused to a catalytically-  
31 inactive USP21. Strikingly, human MLKL, which is very resistant to auto-activation (Tanzer,  
32 Matti et al. 2016, Petrie, Sandow et al. 2018), was auto-activated by the USP21 fusion  
33 suggesting that ubiquitylation is a major brake on the activation of human MLKL.

This article is protected by copyright. All rights reserved

## 1 Results

2

### 3 MLKL becomes ubiquitylated during necroptosis

4 MLKL has previously been reported to undergo ubiquitylation in mouse bone marrow-  
5 derived macrophages (BMDMs) stimulated with the necroptotic stimulus: LPS/Smac-  
6 mimetic (Compound A)/pan-caspase inhibitor (Q-VD-OPh) (Lawlor, Khan et al. 2015). To  
7 test whether MLKL ubiquitylation is specific to necroptosis, we stimulated wildtype mouse  
8 dermal fibroblasts (MDFs) with TNF, Smac-mimetic and the pan-caspase inhibitor IDN-6556  
9 (TSI) individually or in combination for 3 hrs. GST-UBA immobilised on glutathione  
10 sepharose beads (Hospenthal, Mevissen et al. 2015, Stafford, Lawlor et al. 2018) was used to  
11 purify ubiquitylated proteins from cell lysates. These purified samples generated a distinct  
12 ladder of between 50 and 75 kDa when probed with anti-MLKL, which corresponds to non-  
13 ubiquitylated MLKL, mono-ubiquitylated MLKL and multi-ubiquitylated MLKL (**Fig. 1A**).  
14 Though it is unclear why non-ubiquitylated MLKL is recovered in the UBA-pull down  
15 system, it does not affect the observation of ubiquitin ladders. Ubiquitylated MLKL species  
16 were only clearly detected for stimuli that promote MLKL phosphorylation (TI and TSI), but  
17 not for stimuli that induce apoptotic cell death (TS) (**Fig. 1A**). Ubiquitylation probably occurs  
18 before or possibly at the same time as membrane permeabilization, because by the time of  
19 UBA-PD for MDFs (3 hrs) and HT29 cells (16 hrs), cells were at least 60% propidium iodide  
20 (PI)-positive (**Fig. EV1A**).

21

22 As expected, TSI failed to induce MLKL ubiquitylation in *Tnfr1*<sup>-/-</sup> MDFs, but, interestingly,  
23 did not completely prevent all TSI induced MLKL phosphorylation (**Fig. 1B**). Furthermore,  
24 the kinase activities of RIPK1 and RIPK3 were required for MLKL ubiquitylation because  
25 genetic deletion of *Ripk3*, or treatment with the RIPK1 and RIPK3 inhibitors, Nec-1 and  
26 GSK872, respectively, prevented MLKL ubiquitylation (**Fig. 1B**). MLKL phosphorylation  
27 and ubiquitylation were not, however, reduced by genetic deletion of *Traf2* (**Fig. 1B**). To test  
28 whether MLKL ubiquitylation occurred in other cell types, we examined mouse BMDMs.  
29 Necroptosis can be induced in BMDMs by a range of different ligands including LPS, Poly  
30 I:C and the TNF- receptor superfamily ligand FasL, when they are combined with a Smac-  
31 mimetic and a caspase inhibitor, IDN-6556 (SI) (Holler, Zaru et al. 2000, Kaiser, Sridharan et  
32 al. 2013). To exclude a role for autocrine TNF, whose synthesis can be induced by a Smac-  
33 mimetic, LPS, poly I:C or FasL, we compared BMDMs isolated from *Tnfr1*<sup>-/-</sup> and WT mice,

This article is protected by copyright. All rights reserved

1 and saw the same MLKL ubiquitin laddering pattern in both. This ubiquitylation correlated  
2 with MLKL phosphorylation on S345, a well-known hallmark of MLKL activation and  
3 necroptosis (**Fig. 1C**) (Murphy, Czabotar et al. 2013). We and others have shown that human  
4 and mouse MLKL are regulated distinctly (Li, Xu et al. 2015, Tanzer, Matti et al. 2016,  
5 Davies, Tanzer et al. 2018, Petrie, Sandow et al. 2018, Davies, Fitzgibbon et al. 2020),  
6 therefore to see whether human MLKL was also ubiquitylated during necroptosis, we treated  
7 the human colonic adenocarcinoma HT29 cell line with TSI. Although induction of  
8 necroptosis takes longer in HT29 than in MDFs (**Fig. EV1B**), we observed similar MLKL  
9 phosphorylation and ubiquitylation in HT29 cells as in MDFs with similar levels of cell death  
10 (**Fig. 1D, Fig. EV1B**).

11  
12 To determine to what extent upstream necroptotic signalling was required for MLKL  
13 ubiquitylation, we used a well-established RIPK3 dimerisation strategy to activate RIPK3 in  
14 the absence of necroptotic signals (Moujalled, Cook et al. 2014, Orozco, Yatim et al. 2014).  
15 We therefore stably expressed a doxycycline-inducible RIPK3-gyrase fusion protein, which  
16 can be dimerized and activated by coumermycin (Moujalled, Cook et al. 2014), in *Ripk3*<sup>-/-</sup>  
17 MDFs. As expected, forced dimerization of RIPK3 induced MLKL phosphorylation but was  
18 also able to induce MLKL ubiquitylation independent of TSI stimulation and to similar levels  
19 as TSI, indicating that RIPK3 dimerization and activation is sufficient to induce MLKL  
20 ubiquitylation (**Fig. 1E**).

21  
22 **MLKL is ubiquitylated on multiple sites during necroptosis**  
23 Ubiquitin can be coupled to, predominantly, lysine residues in target proteins. Ubiquitin itself  
24 contains 8 ubiquitylation sites (M1, K6, K11, K27, K29, K33, K48 and K63), which leads to  
25 the formation of ubiquitin chains of varying architectures. Differently linked Ub chains serve  
26 distinct functions in cells (Swatek and Komander 2016). To investigate the ubiquitin  
27 architecture on MLKL, we purified ubiquitylated proteins from necroptotic cells using  
28 sepharose beads coupled with GST-UBA and digested them on the beads with a set of  
29 linkage selective deubiquitylating enzymes (UbiCRest) (Hospenthal, Mevissen et al. 2015).  
30 Each DUB specifically recognizes and removes a known subset of poly-ubiquitin chain type  
31 with validated activity (**Fig. 2A**) (Stafford, Lawlor et al. 2018). The non-specific DUB,  
32 USP21, (Ye, Akutsu et al. 2011) converted MLKL into a non-ubiquitylated form, but the  
33 other chain-specific DUBs made no discernible difference to the MLKL ubiquitin laddering

This article is protected by copyright. All rights reserved

1 pattern (**Fig. 2B**). To control that there was sufficient DUB activity we decreased the ratio of  
2 substrate to DUBs to 1/2 and 1/4 (**Fig. 2C**). vOTU, a DUB that can cleave every type of poly-  
3 ubiquitin chain except M1-linked chains, deubiquitylated most ubiquitylated proteins (see  
4 total ubiquitin blot, **Fig. 2C**), yet it only deubiquitylated the highest molecular weight species  
5 of MLKL~Ub adducts, and did not affect bands representing the lower molecular weight  
6 MLKL~Ub species. No changes were observed upon treatment with OTULIN, a DUB  
7 specific for M1-linked ubiquitin chains (Keusekotten, Elliott et al. 2013), indicating that the  
8 residual Ub left by vOTU are not M1-linked ubiquitin chains. Given that USP21 is the only  
9 DUB in the tested panel that can cleave the covalent bond between a protein substrate and the  
10 first ubiquitin unit added, these data suggest that ubiquitylated MLKL is most likely mono-  
11 ubiquitylated at multiple sites.

### 12 13 **MLKL ubiquitylation accumulates in the membrane fraction and can be** 14 **deubiquitylated by USP21 localised to the plasma membrane**

15 During necroptosis, activated MLKL oligomerises and translocates to biological membranes,  
16 ultimately causing membrane rupture and cell death (Cai, Jitkaew et al. 2014, Chen, Li et al.  
17 2014, Hildebrand, Tanzer et al. 2014). To understand more about MLKL ubiquitylation, we  
18 examined when and where this occurs. WT MDFs were stimulated with TSI over a time  
19 course from 30 to 180 minutes. Cytosolic and crude membrane fractions were generated as  
20 previously described using digitonin (Liu, Silke et al. 2018), and subjected to UBA-pull  
21 down. We refer to the 0.025% digitonin insoluble fraction as 'crude membrane', but do not  
22 exclude the potential for non-membrane associated large macromolecular/amyloid-like  
23 structures to sediment along with crude membranes (Liu, Liu et al. 2017). Ubiquitylated  
24 MLKL emerged and accumulated within the whole cell lysate and the crude membrane  
25 fraction from 90 minutes post-stimulus onwards, coinciding precisely with the appearance of  
26 phosphorylated MLKL and onset of cell death (**Fig. 3A & Fig. EV1A**). On the other hand,  
27 the predominant species of MLKL in the cytosol was non-phosphorylated and non-  
28 ubiquitylated (**Fig. 3A**). These data suggest that MLKL ubiquitylation occurs in the crude  
29 membrane fraction but not in the cytosol.

30  
31 To explore further where ubiquitylated MLKL is located we took advantage of the fact that  
32 ubiquitylated MLKL was digested by USP21 (**Fig. 2B**). We therefore fused a CaaX motif tag  
33 (C=cysteine, a=aliphatic amino acid, X=terminal residue) to the C-terminus of the catalytic  
34 domain USP21 to localise it to the plasma membrane (Hancock, Cadwallader et al. 1991).

This article is protected by copyright. All rights reserved

1 We chose 'CVLQ' to mimic the CaaX motif found at the C-terminal end of another DUB,  
2 USP32 (Sapmaz, Berlin et al. 2019), and also generated a catalytically-dead USP21 mutant  
3 version (USP21<sup>C221R</sup>) as a control, also fused with CaaX motif. This mutant, like the  
4 previously published mutant USP21<sup>C221A</sup>, lacks the ability to remove ubiquitin (Ye, Akutsu et  
5 al. 2011, Ye, Blaser et al. 2012, Morrow, Morgan et al. 2018). Using these stably and  
6 inducibly expressed constructs we evaluated TSI-mediated MLKL ubiquitylation with or  
7 without USP21-CaaX function. Taking into account the amount of MLKL in the crude  
8 membrane fraction it was clear that while it did not completely denude MLKL of ubiquitin,  
9 the WT USP21-CaaX fusion did substantially reduce the amount of ubiquitylated MLKL, as  
10 well as generally affecting the levels of ubiquitylated proteins (**Fig. 3B**), although it did not  
11 reduce the kinetics of either apoptosis or necroptosis (**Fig. EV2**). Taken together these data  
12 suggest that ubiquitylated MLKL is localised to the plasma membrane.

13

#### 14 **Necroptosis induced MLKL ubiquitylation is driven by its oligomerization**

15 In order to kill, MLKL oligomerizes, translocates to, and permeabilises membranes. To  
16 dissect further the drivers of MLKL ubiquitylation, we generated a series of MLKL mutants  
17 that were defective in one or more of these essential steps. Previously, we found that alanine  
18 replacement of the surface exposed residues R105 and D106 in the four-helix bundle (4HB)  
19 domain of mouse MLKL prevents it from oligomerising, translocating and inducing cell  
20 death (Hildebrand, Tanzer et al. 2014, Tanzer, Matti et al. 2016). In the context of full length  
21 MLKL, we found that these mutations prevent formation of a high molecular weight complex  
22 (complex II) in the 'crude membrane' fraction following necroptotic stimulation by TSQ (**Fig.**  
23 **4A**). Although R105A/D106A MLKL was phosphorylated following this necroptotic  
24 stimulus, it did not exhibit the distinct TSI-induced ubiquitylation observed for WT MLKL  
25 (**Fig. 4B**). This supports the idea that MLKL only undergoes ubiquitylation post activation by  
26 RIPK3 and suggests that MLKL does not undergo ubiquitylation without oligomerization.

27

28 The MLKL mutants, Q343A (which perturbs a hydrogen bond with K219 in the ATP binding  
29 motif VTIK) and S345D (phospho-mimetic), are auto-activated forms of murine MLKL  
30 (Murphy, Czabotar et al. 2013). We induced expression of Q343A or S345D mutant MLKL  
31 in *Mlkl*<sup>-/-</sup> and *Ripk3*<sup>-/-</sup>*Mlkl*<sup>-/-</sup> MDFs for 16 hrs where, as predicted, they killed cells  
32 independently of an extrinsic necroptotic stimulus (**Fig. EV3B**). As expected, induction of  
33 necroptosis in *Mlkl*<sup>-/-</sup> cells reconstituted with wild type MLKL resulted in MLKL  
34 ubiquitylation (**Fig. 4C**). However, activated MLKL mutants expressed in the same *Mlkl*<sup>-/-</sup>

This article is protected by copyright. All rights reserved

1 MDFs were ubiquitylated independently of a necroptotic stimulus and to an extent  
2 comparable to wildtype MLKL induced to undergo necroptosis (Fig. 4C). Furthermore,  
3 Q343A MLKL became ubiquitylated in *Ripk3<sup>-/-</sup>Mkl1<sup>-/-</sup>* MDFs and therefore independently of  
4 any upstream activation (Fig. 4D). We conclude that while MLKL ubiquitylation correlates  
5 with its oligomerization and phosphorylation, direct RIPK3 association is not required for  
6 MLKL ubiquitylation in murine cells.

7  
8 Necrosulfonamide (NSA) is an inhibitor of human MLKL by forming a covalent bound with  
9 Cys86 that only exists in human MLKL but not mouse MLKL (Liu, Liu et al. 2017).  
10 Consistent with a recent report (Murai, Yamaguchi et al. 2018, Samson, Zhang et al. 2020),  
11 we found that while it did not inhibit the phosphorylation of MLKL or the formation of high  
12 molecular weight MLKL-containing complex, large proportions of this MLKL species  
13 remained in the cytosolic (0.025% digitonin soluble) fraction (C) of cells (Fig. 4E).  
14 Consistent with the reduction in MLKL oligomer in the crude membrane (0.025% digitonin  
15 insoluble) fraction (M), NSA also reduced MLKL ubiquitylation (Fig. 4F).

#### 16 **Ubiquitylated MLKL undergoes proteasome and lysosome dependent turnover**

17 Unlike the R105A/D106A MLKL mutant, E109A/E110A MLKL mutant and N-terminal  
18 FLAG-tagged MLKL (N-FLAG MLKL) are able to form higher order oligomers in crude  
19 membrane fractions following necroptotic stimulation, yet are, nevertheless, unable to induce  
20 necroptosis (Hildebrand, Tanzer et al. 2014, Tanzer, Matti et al. 2016) (Fig. 5A, B, Fig.  
21 EV4A, B). These mutants therefore allowed us to examine whether ubiquitylation was a  
22 consequence of necroptosis. Upon induction of necroptosis, E109A/E110A MLKL was more  
23 heavily phosphorylated and ubiquitylated than wildtype MLKL (Fig. 5C). Similarly, N-  
24 FLAG MLKL was also phosphorylated and ubiquitylated within 2 hrs of TSI treatment,  
25 although these modified MLKL species diminished over time (Fig. 5D).

26  
27  
28 The cellular turnover of active forms of MLKL has been observed previously by our group  
29 and by others (Gong, Guy et al. 2017, Yoon, Kovalenko et al. 2017, Zargarian, Shlomovitz et  
30 al. 2017, Hildebrand, Kauppi et al. 2020). Therefore, we examined ubiquitylation of N-FLAG  
31 MLKL in MDFs over a time course following a TSI pulse. N-FLAG MLKL is  
32 phosphorylated, oligomerizes and accumulates in the 0.025% insoluble cell fraction without  
33 killing *Mkl1<sup>-/-</sup>* MDFs following necroptotic stimulation. This later feature facilitates the study  
34 of these ubiquitylated MLKL species and their cellular turnover *in situ* using proteasome and

This article is protected by copyright. All rights reserved

1 lysosome inhibitors as previously described for unmodified MLKL (Hildebrand et al, 2020).  
2 We found that after 4 hrs TSI stimulation, levels of ubiquitylated and phosphorylated N-  
3 FLAG MLKL dramatically decreased. This decrease can be delayed by either the lysosome  
4 inhibitor bafilomycin or the proteasome inhibitor PS341 (**Fig. 5E**). This suggests that MLKL  
5 ubiquitylation correlates with its proteasome and lysosome dependent turnover.

#### 6 7 **MLKL ubiquitylation antagonises necroptosis**

8 We sought to identify the precise amino acids on MLKL that were modified by ubiquitin. We  
9 enriched for activated and ubiquitylated N-FLAG MLKL from the 'crude membrane' fraction  
10 of MDFs by performing a FLAG tag affinity purification. Eluted fractions from FLAG  
11 affinity beads were analysed by mass spectrometry, which identified Gly-Gly conjugates on  
12 lysine residues K9, K51, K69 and K77 (**Fig. EV5A**). All four are located in the 4HB domain  
13 of MLKL (**Fig. EV5B**) which suggests a role for ubiquitylation in regulating MLKL-  
14 mediated cell death. We did not identify any additional signs of ubiquitin modification on the  
15 brace or pseudokinase region of MLKL using this experimental system.

16  
17 We mutated the four lysines to arginine and inducibly expressed the "4KR" mutant in *Mkl1*<sup>-/-</sup>  
18 MDFs to explore their role. Surprisingly, the 4KR MLKL was phosphorylated and  
19 ubiquitylated in a similar manner to wild type MLKL following TSI treatment (**Fig. 6B**).  
20 There was a reduction in the ability of this mutant to kill cells in response to TSI treatment  
21 (**Fig. EV5C**), but this is seemingly unrelated to its ubiquitylation and more likely due to  
22 modification of conserved residues in the cytotoxic domain of MLKL. These results highlight  
23 the difficulties in mutational analyses when studying ubiquitylation and rather than mutate  
24 any of the other 38 lysines in MLKL we tried a different approach.

25  
26 We had observed that the deubiquitylating enzyme USP21 removed all ubiquitin from MLKL  
27 *in vitro* (**Fig. 2B**). We therefore hypothesised that fusing the catalytic domain of USP21 to  
28 MLKL would remove TSI induced ubiquitylation from MLKL. We fused it to the C-terminal  
29 end of MLKL, because, as with the FLAG tag, N-terminal fusions affect the ability of MLKL  
30 to kill (**Fig. EV4A**). We fused the catalytic domain of USP21 to the C-terminus of both  
31 human and mouse MLKL (**Fig. 7A**) and expressed the fusion proteins in *MLKL*<sup>-/-</sup> HT29 and  
32 *Mkl1*<sup>-/-</sup> MDF cells respectively, to determine, firstly, whether it still retained cytotoxic activity  
33 and, secondly, whether it would be resistant to necroptosis induced ubiquitylation. To  
34 specifically control for the loss of ubiquitylation, we also generated MLKL fused to the

This article is protected by copyright. All rights reserved

1 previously described catalytically-dead USP21 mutant (USP21<sup>C221R</sup>; **Fig. 3B, 7A**). Both the  
2 MLKL-USP21 and MLKL-USP21<sup>C221R</sup> fusion proteins were exogenously expressed and the  
3 cells were stimulated with TSI for varying amounts of time. Ubiquitylated proteins were  
4 enriched *via* UBA-pulldown. Like murine MLKL<sup>WT</sup>, the catalytically inactive control,  
5 MLKL-USP21<sup>C221R</sup>, when expressed in *Mkl1*<sup>-/-</sup> MDFs, showed high MW laddering indicative  
6 of ubiquitylation and the ubiquitylation was enhanced following TSI stimulation (**Fig. 7B**).  
7 These high MW MLKL-USP21<sup>C221R</sup> species were reduced and collapsed into non-  
8 ubiquitylated form by digestion of recombinant USP21 (**Fig. EV6C**). In contrast, the  
9 ubiquitin laddering was not evident for the MLKL-USP21<sup>WT</sup> fusion (**Fig. 7B**). MLKL-USP21  
10 and MLKL-USP21<sup>C221R</sup> re-constituted sensitivity to TSI stimulation in *Mkl1*<sup>-/-</sup> MDFs with  
11 only modestly delayed kinetics when compared to wildtype MLKL (**Fig. 7C**). However,  
12 unlike wildtype MLKL or MLKL-USP21<sup>C221R</sup>, MLKL-USP21 could induce cell death  
13 independent of TSI stimulation (**Fig. 7C**), even when expressed in *Ripk3*<sup>-/-</sup>*Mkl1*<sup>-/-</sup> MDFs (**Fig.**  
14 **7C**).

15  
16 We made similar observations for human MLKL-USP21 fusions expressed in *MLKL*<sup>-/-</sup> HT29  
17 cells. Human MLKL-USP21<sup>C221R</sup>, but not MLKL-USP21 fusions, became ubiquitylated  
18 following TSI stimulation (**Fig. 7E**). Furthermore, like human MLKL, human MLKL-USP21  
19 and MLKL-USP21<sup>C221R</sup> fusions were able to reconstitute the capacity of *MLKL*<sup>-/-</sup> HT29 cells  
20 to undergo TSI induced necroptosis when their expression was induced by doxycycline (**Fig.**  
21 **7D**), while USP21 controls did not (**Fig. EV6B**). NSA was able to delay TSI-induced cell  
22 death for all MLKL species, but became less effective over time, presumably overwhelmed  
23 by ongoing expression of MLKL. Induced expression of MLKL-USP21 also caused TSI-  
24 independent cell death from 16 hrs, without detectable MLKL phosphorylation ( $t_0 = 25$  hrs  
25 induction, **Fig. 7E**), and this could also be delayed by NSA (**Fig. 7D**). These data indicate  
26 that ubiquitylation of acts as an important kinetic regulator of the necroptosis pathway  
27 following oligomerization and membrane association.

## 28 29 **Discussion**

30 MLKL undergoes ubiquitylation during necroptosis. In this study, we identified a distinctive  
31 ubiquitylation of both mouse and human MLKL that could be induced by a range of  
32 necroptotic stimuli. This signature ubiquitin ladder was essentially resistant to cleavage by a  
33 host of DUBs. Only USP21, the DUB that can remove all ubiquitin modifications, including

1 mono-ubiquitylation, was able to deubiquitylate MLKL. Therefore, we propose that MLKL is  
2 mono-ubiquitylated at multiple sites. Mono-ubiquitylation is typically associated with  
3 endosome-lysosome trafficking (Haglund, Sigismund et al. 2003, Mosesson and Yarden 2006)  
4 and is less likely to play a scaffolding role or result in proteasomal degradation (Wilkinson,  
5 Tashayev et al. 1995, Oh, Akopian et al. 2018).

6  
7 Full activation of MLKL's killing activity is a multi-step and protracted process, the  
8 choreography of which has not yet been fully deduced. Nevertheless there is a broad  
9 consensus, based on analysis of MLKL mutants and a range of different techniques, that  
10 phosphorylation by RIPK3 leads to MLKL oligomerization, translocation to biological  
11 membranes and subsequent membrane permeabilisation (Tanzer, Matti et al. 2016, Petrie,  
12 Sandow et al. 2018, Petrie, Birkinshaw et al. 2020, Samson, Zhang et al. 2020). Recent  
13 single-cell imaging approaches examining human MLKL show that phosphorylated MLKL  
14 clusters in cytoplasmic vesicles together with RIPK1. These vesicles are actively transported  
15 to the plasma membrane, where they begin to coalesce in hotspots, some hours prior to  
16 membrane lysis (Samson, Zhang et al. 2020). Consistent with data showing that NSA does  
17 not prevent MLKL phosphorylation or initial oligomerization, but does block higher order  
18 oligomerization (Liu, Liu et al. 2017), NSA appears to prevent MLKL clustering (Samson,  
19 Zhang et al. 2020). To define where and when ubiquitylation of MLKL occurred we  
20 fractionated cells into cytosolic and crude membrane fractions, and only detected  
21 ubiquitylated MLKL in the 0.025% digitonin insoluble (crude membrane) fraction. We also  
22 examined a number of different MLKL mutants that we had previously characterised for their  
23 ability to form oligomers, translocate to the crude membrane fraction and promote  
24 necroptosis. The MLKL mutants, Q343A and S345D, which are able to form 0.025%  
25 digitonin insoluble high molecular weight oligomers and induce cell death without  
26 necroptotic stimulation (Murphy, Czabotar et al. 2013, Tanzer, Tripaydonis et al. 2015), were  
27 ubiquitylated independently of RIPK3 or a necroptotic TSQ stimulus. On the other hand, the  
28 R105A/D106A mutant that is unable to form high molecular weight oligomers on BN-PAGE  
29 did not become ubiquitylated following a necroptotic stimulus. This implies that MLKL  
30 ubiquitylation occurs after MLKL oligomerization and does not specifically require RIPK3 or  
31 upstream signalling.

32  
33 MLKL has been variously reported to traffic to the nucleus (Yoon, Bogdanov et al. 2016,  
34 Weber, Roelandt et al. 2018), lysosomes (Wang, Sun et al. 2014, Yoon, Kovalenko et al.

This article is protected by copyright. All rights reserved

1 2017, Fan, Guo et al. 2019), mitochondria (Wang, Jiang et al. 2012) and the plasma  
2 membrane (Cai, Jitkaew et al. 2014, Chen, Li et al. 2014, Hildebrand, Tanzer et al. 2014,  
3 Samson, Zhang et al. 2020) following necroptotic activation. Crude membrane fractionation  
4 enriches membrane and insoluble protein aggregates, therefore in an attempt to determine  
5 more precisely where MLKL ubiquitylation occurred, we generated a plasma membrane-  
6 targeted, CaaX-fused USP21 (Wright and Philips 2006). Because ubiquitin modification  
7 plays a role in the initial, plasma membrane located, TNF/TNFR1 induced necroptotic  
8 signalling, we anticipated that expressing USP21-CaaX might affect induction of necroptosis.  
9 However necroptosis was induced in cells expressing a non-targeted USP21 or a catalytically  
10 inactive USP21<sup>C221R</sup>-CaaX to equal levels as in USP21-CaaX cells, despite the fact that  
11 USP21-CaaX was clearly active and reduced total ubiquitin levels. Consistent with MLKL  
12 being targeted to the plasma membrane, MLKL was less ubiquitylated in USP21-CaaX cells  
13 than in cells expressing USP21<sup>C221R</sup>-CaaX following a necroptotic stimulus. MLKL  
14 ubiquitylation was, however, not completely prevented by USP21-CaaX expression leaving  
15 open several interpretations of this data, viz: not all MLKL is ubiquitylated at the plasma  
16 membrane; or USP21-CaaX was unable to access all MLKL in the membrane; or MLKL is  
17 ubiquitylated prior to reaching the plasma membrane and can only be deubiquitylated once it  
18 arrives there. Therefore while we cannot exclude that ubiquitylated MLKL sediments as part  
19 of large amyloid-like polymers or large cytoskeletal structures in the crude membrane  
20 fraction without being directly associated with a biological membrane (Liu, Liu et al. 2017),  
21 our data suggest that at least some ubiquitylated MLKL is accessible to a plasma membrane  
22 localised DUB.

23  
24 As previously observed (Murai, Yamaguchi et al. 2018), we found that in the presence of  
25 NSA, the high molecular weight human MLKL complex that is normally found exclusively  
26 in the crude membrane fraction was now also observed in the cytosolic fraction. Combined  
27 with other observations (Samson, Zhang et al. 2020), this indicates that NSA interferes with  
28 MLKL membrane association. Since NSA treatment also inhibited MLKL-ubiquitylation,  
29 this suggests that membrane association is required for MLKL ubiquitylation, and that the  
30 relevant E3 ligase is also membrane associated.

31  
32 Neither N-terminally FLAG tagged MLKL nor the E109A/E110A mutant MLKL are capable  
33 of killing cells, although both are phosphorylated and form 0.025% digitonin-insoluble high  
34 molecular weight oligomers in a similar manner to wild type MLKL following induction of

This article is protected by copyright. All rights reserved

1 necroptosis. Since both are also ubiquitylated we can conclude that ubiquitylation is not  
2 sufficient to cause necroptosis. To more precisely define the role of MLKL ubiquitylation  
3 during necroptosis we used mass spectrometry to identify ubiquitylated lysines in mouse  
4 MLKL. We found four such lysines in the 4HB domain, but none in the pseudokinase domain.  
5 Only one of these four, K77, is conserved in human MLKL, however this is not particularly  
6 surprising because homology of charged residues in MLKL is not well conserved between  
7 mouse and human (**Fig. EV5B**). While this manuscript was in preparation, another group  
8 reported activation dependent MLKL ubiquitylation at residues K51, K77, K172 and K219 ,  
9 showing more possible MLKL ubiquitylation sites in other contexts (Garcia, Tenev et al.  
10 2021).

11  
12 Mutation of these lysines did not prevent either MLKL induced killing or MLKL  
13 ubiquitylation. The persistence of ubiquitin modification is a relatively common scenario  
14 when trying to define the role of ubiquitylation by mutating lysine. This is because E3 ligase  
15 mediated ubiquitylation is rarely tightly restricted to a motif and can therefore be  
16 promiscuous in target modification (Petroski and Deshaies 2003, Wu, Xu et al. 2003). This  
17 means that if a favoured lysine in the target is mutated, the E3 ligase may nevertheless  
18 ubiquitylate another lysine. We therefore tried a more innovative approach. Since we had  
19 shown that the DUB USP21 was able to remove necroptosis induced ubiquitylation of MLKL  
20 *in vitro*, we generated an MLKL C-terminal USP21 fusion that we predicted would be  
21 constitutively deubiquitylated. A similar approach fusing the K63 specific DUB AMSH to  
22 EGFR has been used to investigate EGFR degradation (Huang, Zeng et al. 2013), however it  
23 was not clear whether a DUB that removes all ubiquitin would be as well tolerated by cells.  
24 Stable inducible expression of USP21 alone was not toxic to cells over 24 hours and fusion of  
25 the wildtype or catalytically-dead USP21 did not markedly affect MLKL's cytotoxic activity  
26 following a TSI death stimulus. Furthermore, catalytically-active USP21 fused to MLKL  
27 prevented TSI induced ubiquitylation of MLKL. Interestingly, in both human and mouse  
28 cells, loss of MLKL ubiquitylation also allowed MLKL to kill cells without a necroptotic  
29 stimulus, albeit less potently when compared with such a stimulus. This further supports the  
30 idea that ubiquitylation of MLKL is an important 'insurance policy' against low level  
31 activation of MLKL by other cellular kinases or low level spontaneous transition to the active  
32 conformation. Furthermore our results indicate that the approach of directly fusing a DUB,

This article is protected by copyright. All rights reserved

1 even a pan DUB like USP21, to a protein of interest may be a widely applicable technique to  
2 evaluate the role of ubiquitin modification in other systems.

3  
4 Other mechanisms have been proposed for MLKL turnover post-activation. The ESCRT-III  
5 machinery was proposed to mediate plasma membrane shedding alongside active MLKL  
6 during necroptosis (Gong, Guy et al. 2017), and cells were reported to release active MLKL  
7 containing vesicles via endosomal trafficking (Yoon, Kovalenko et al. 2017, Zargarian,  
8 Shlomovitz et al. 2017, Fan, Guo et al. 2019). It has been proposed that this turnover helps  
9 set a threshold of activated MLKL required for necroptosis and that it delays the onset of cell  
10 death to allow production of essential cytokines and Damage-associated molecular patterns  
11 (DAMPs) and an inflammatory response (Vandenabeele, Riquet et al. 2017). Another  
12 possibility is that the prolonged multi-step path from MLKL phosphorylation to membrane  
13 permeabilisation and cell death allows multiple points of regulation that ensure that a cell  
14 only commits to necroptosis under precisely defined conditions (Jacobsen, Lowes et al. 2016,  
15 Dovey, Diep et al. 2018, Hildebrand, Kauppi et al. 2020, Samson, Zhang et al. 2020). For this  
16 to work, the cell must have mechanisms to deactivate already activated MLKL, and the  
17 ubiquitylation of MLKL may serve as one such mechanism. Our results, showing that  
18 MLKL-USP21, but not a wild type MLKL expressed to similar levels, kills cells in the  
19 absence of a necroptotic stimulus suggest that MLKL may be continually translocating to  
20 membranes and turned over by MLKL-ubiquitylation. Like the rapid degradation of  
21 inflammatory cytokine mRNAs (Lacey, Hickey et al. 2015, Menon and Gaestel 2018)  
22 although energetically costly, this might allow a more rapid response to a pathogen than an  
23 on/off mechanism focused solely on initiation and may also provide another mechanism to  
24 detect and act on attempts by pathogens to interfere with this anti-pathogen response.

25

## 26 **Materials and Methods**

27

### 28 **Compound and cytokines**

29 Human TNF-Fc made in-house, Smac-mimetics Compound A (Tetralogic), IDN-6556  
30 (Tetralogic), Q-VD-OPh (R & D Systems), Lipopolysaccharide (LPS, Sigma), Poly I:C  
31 (Sigma), Fas Ligand (a gift from Lorraine O'Reilly, WEHI), doxycycline (Sigma),  
32 Necrostatin-1 (Nec-1, Sigma), GSK872 (a gift from Anaxis Pty, Ltd.), coumermycin (Sigma),  
33 Necrosulfonamide (NSA, Merck Millipore), Propidium iodide (Sigma), Sytox Green  
34 (Thermo Fisher), puromycin (Thermo Fisher), N-ethylmaleimide (NEM, Sigma),

This article is protected by copyright. All rights reserved

1 deubiquitylase (DUBs) made in house (Hospenthal, Mevissen et al. 2015), complete protease  
2 inhibitor cocktail (Roche), Bafilomycin A1 (BAF, Enzo), PS341 (Sigma).

3

#### 4 **Antibodies:**

5 Mouse phospho-MLKL (Ser345) rabbit monoclonal ERP9515(2) (Abcam)

6 Mouse phospho-MLKL (Ser345) rabbit monoclonal (D6E3G) (Cell Signalling Technology)

7 MLKL rat monoclonal 3H1 (available from Millipore MABC604; generated in-house)

8  $\beta$ -actin mouse monoclonal AC-15 (Sigma A-1978)

9 BAK NT rabbit polyclonal #06-536 (EMD Millipore)

10 GAPDH rabbit monoclonal 14C10 (Cell Signalling Technology)

11 Pan-ubiquitin mouse monoclonal #3939 (Cell Signalling Technology)

12 Mouse/human RIPK1 mouse monoclonal #610458 (BD transduction Laboratories)

13 Mouse RIPK3 rabbit polyclonal PSC-2283-c100 (Axxora (Pro Sci))

14 Human RIPK3 rat monoclonal 1H2 (generated in-house)(Petrie, Sandow et al. 2019)

15 Human phospho-MLKL (Ser358) rabbit monoclonal ab 187091 (Abcam)

16 VDAC1 rabbit polyclonal AB10527 (Millipore)

17 Human Usp21 rabbit polyclonal 17856-I-AP (Proteintech)

18 HRP-conjugated secondary antibodies

19

#### 20 **Cell lines immortalisation and transfection**

21 Cells were cultured in DMEM+8% FCS at 37°C. HT29 cells were a kind gift from Mark  
22 Hampton. MDFs were isolated from tails of mice bearing different genotype, and  
23 immortalized by SV40 large T antigen via lentivirus transduction. MLKL mutant constructs  
24 were generated as described previously ((Murphy, Czabotar et al. 2013, Hildebrand, Tanzer  
25 et al. 2014, Moujalled, Cook et al. 2014)). All oligonucleotides for PCR and mutagenesis  
26 were synthesized by IDT. Constructs encoding USP21 catalytic domain with GS linker were  
27 made by GenScript (Nanjing, CN). Genes encoding WT mouse MLKL and PCR-derived  
28 mutants were cloned into pF TRE3G PGK puro, a puromycin-selectable, doxycycline-  
29 inducible vector as previously described (and kindly supplied by Toru Okamoto) (Murphy,  
30 Czabotar et al. 2013, Hildebrand, Tanzer et al. 2014, Moujalled, Cook et al. 2014, Tanzer,  
31 Matti et al. 2016). Lentiviruses were generated in HEK293T cells before infection of target  
32 cells. Puromycin (5  $\mu$ g/mL) was added for selection and maintenance of lines stably  
33 transduced with lentivirus.

This article is protected by copyright. All rights reserved

1  
2 For BMDMs, femora and tibiae were collected from WT and *Tnf*<sup>-/-</sup> mice at 6 weeks old, cut  
3 and flushed by PBS. Bone marrow were incubated in Petri dishes with DMEM supplemented  
4 with 10% FCS and 20% conditioned L929 medium for 7 days. Cells were fed with fresh  
5 medium after 3 days of plating.

#### 6 7 **Concentrations of stimuli and inhibitors**

8 TNF (100 ng/mL), Smac-mimetic Compound A (500 nM), IDN-6556 (5  $\mu$ M), Q-VD-OPh (5  
9  $\mu$ M), doxycycline (20 ng/mL), Necrostatin-1 (50  $\mu$ M), GSK872 (5 mM), LPS (50 ng/mL),  
10 Fas ligand (6.4 ng/mL), Poly I:C (1 mg/mL), coumermycin (700 nM), Bafilomycin (5  $\mu$ M),  
11 PS341 (50 nM), MG132 (200nM), Chloroquine (50  $\mu$ M), NH<sub>4</sub>Cl (2 mM), Ca-074 Me (20  
12  $\mu$ M), TLCK (100  $\mu$ M), AEBSF (100  $\mu$ M) and concentrations otherwise indicated.

#### 13 14 **Cell death measured by flow cytometry**

15 Cells were plated at 50,000/well in 24-well plates before treatment, collected by trypsin and  
16 spun down, resuspended and stained with PI (Propidium Iodide, 1  $\mu$ g/mL) in PBS buffer, and  
17 quantified by Flow cytometry.

#### 18 19 **Cell death measured by live cell imaging**

20 MDFs were plates at 10,000/well or 15,000/well (96-well plates) and HT29s were plated at  
21 40,000/well (48-well plates) or 15,000/well (96-well plates) and allowed to settle for 4 hrs  
22 (MDFs) and 24 hrs (HT29s) respectively. Cells were stimulated as indicated in media  
23 containing Propidium Iodide (PI, 200 ng/mL) or Sytox Green (500nM, ThermoFisher  
24 Scientific) and imaged at 45 min or 1 hr intervals using an IncuCyte S3 Live cell imager.  
25 Numbers of PI or Sytox positive cells were quantified and plotted using IncuCyte software.

#### 26 27 **Cellular fractionation and Blue Native-PAGE**

28 Cells were collected by scraping, spun down and washed in pre-chilled PBS. MELB buffer  
29 (20 mM 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid, (HEPES) pH=7.5, 100 mM  
30 sucrose, 2.5 mM MgCl<sub>2</sub>, 100 mM KCl) containing 0.025% digitonin was used to  
31 permeabilise cells to extract the cytosol fraction. Non-soluble part was further solubilized by  
32 1% digitonin buffer. (Schagger and von Jagow 1991, Liu, Silke et al. 2018) Both fractions  
33 were separated by Bis-Tris Native PAGE, and transferred to PVDF membrane. After transfer

1 the membrane was then destained (50% methanol and 25% acetic acid) and denatured (in 6M  
2 guanidine HCl, 5 mM  $\beta$ -ME) to maximise epitope exposure.

3

#### 4 **UBA-pull down assay and UbiCrest**

5 Recombinant GST-UBA fusion protein (Hjerpe, Aillet et al. 2009) purified from *E. coli* in  
6 house was prebound to glutathione sepharose beads (10  $\mu$ L/condition). Cells were lysed in  
7 DISC buffer (30 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol) containing 1% Triton  
8 X-100 with 10 mM NEM and protease inhibitor. Cleared lysate was then coupled with beads  
9 overnight. SDS-PAGE sample loading buffer was used to elute the UBA-pull down fraction.  
10 For UbiCrest, washed beads were then incubated with DUBs at previously established  
11 concentrations (Hospenthal, Mevissen et al. 2015) and incubated at 37°C for the indicated  
12 times. Digestion product was eluted in SDS sample buffer for Western blot analysis.

13

#### 14 **FLAG-tagged protein immunoaffinity precipitation and Mass Spectrometry sample** 15 **preparation**

16 N-FLAG WT mouse MLKL was inducibly expressed in *Mkl1*<sup>-/-</sup> MDFs by doxycycline  
17 overnight and stimulated with TSI for 3 hrs. Cells were collected by scraping and  
18 permeabilised by 0.025% digitonin in MELB buffer together with NEM (10 mM) and  
19 protease inhibitors. The crude membrane fraction was pelleted by centrifugation and  
20 dissolved in 1% SDS in DISC buffer. Cleared lysate of crude membrane was then applied to  
21 M2-FLAG beads for affinity precipitation. FLAG tagged protein on beads was eluted by  
22 heating at 56°C in 0.5% SDS solution. Eluted material was subjected to tryptic digestion  
23 using the FASP method (Wisniewski, Zougman et al. 2009). Peptides were lyophilised using  
24 CentriVap (Labconco) prior to reconstituting in 80  $\mu$ l 0.1% FA/2% acetonitrile (ACN).  
25 Peptide mixtures (1  $\mu$ l) were analysed by nanoflow reversed-phase liquid chromatography  
26 tandem mass spectrometry (LC-MS/MS) on an M-Class HPLC (Waters) coupled to a Q-  
27 Exactive Orbitrap mass spectrometer (Thermo Fisher). Peptide mixtures were loaded in  
28 buffer A (0.1% formic acid, 2% acetonitrile, Milli-Q water), and separated by reverse-phase  
29 chromatography using C<sub>18</sub> fused silica column (packed emitter, I.D. 75  $\mu$ m, O.D. 360  $\mu$ m x  
30 25 cm length, IonOpticks, Australia) using flow rates and data-dependent methods as  
31 previously described (Delconte, Kolesnik et al. 2016, Kedzierski, Tate et al. 2017). Raw files  
32 consisting of high-resolution MS/MS spectra were processed with MaxQuant (version 1.5.8.3)  
33 for feature detection and protein identification using the Andromeda search engine (Cox,

This article is protected by copyright. All rights reserved

1 Neuhauser et al. 2011). Extracted peak lists were searched against the UniProtKB/Swiss-Prot  
2 *Mus musculus* database (October 2016) and a separate reverse decoy database to empirically  
3 assess the false discovery rate (FDR) using strict trypsin specificity allowing up to 2 missed  
4 cleavages. The minimum required peptide length was set to 7 amino acids. The mass  
5 tolerance for precursor ions and fragment ions were 20 ppm and 0.5 Da, respectively. The  
6 search included variable modifications of oxidation (methionine), amino-terminal acetylation,  
7 carbamidomethyl (cysteine), GlyGly or ubiquitylation (lysine), phosphorylation (serine,  
8 threonine or tyrosine) and N-ethylmaleimide (cysteine).

9

#### 10 **Data availability**

11 The raw mass spectrometric data and the MaxQuant result files have been deposited to the  
12 ProteomeXchange Consortium via the PRIDE (Perez-Riverol, Csordas et al. 2019) partner  
13 repository with the dataset identifier: PXD015537  
14 (<http://www.ebi.ac.uk/pride/archive/projects/PXD015537>)

15

#### 16 **Acknowledgements:**

17 We would like to thank Jiami Han, Yueyuan Li and the WEHI mouse facility for technical  
18 assistance. This work was funded by NHMRC grants 1025594 (JS), 1046984 (JS) and  
19 1105023 (JS and JMH) and fellowships 1172929 (JMM), 1058190 (JS), 1107149 (JS) and  
20 110574 (JS) and was made possible through Victorian State Government Operational  
21 Infrastructure Support and Australian Government NHMRC IRIISS (9000587).

22

#### 23 **Author Contribution**

24 ZL, LD and KSA designed and performed experiments, and analysed data. SNY, AB, XW,  
25 MT, CAS, CF, and SEG performed experiments. JH, UN, JMM and AIW provided methods  
26 and resources. ZL, JMH and JS analysed the data and wrote the manuscript. DK conceived  
27 the DUB fusion experiment and provided reagents. All authors read and commented on the  
28 manuscript.

29

#### 30 **Conflict of interest statement**

31 SNY, AB, UN, CF, SEG, JMM, JMH and JS contribute to, or have contributed to, a project  
32 with Anaxis Pty Ltd to develop necroptosis inhibitors.

33

34

This article is protected by copyright. All rights reserved

## 1 **References**

- 2
- 3 Bertrand, M. J., S. Milutinovic, K. M. Dickson, W. C. Ho, A. Boudreault, J. Durkin, J. W. Gillard,  
4 J. B. Jaquith, S. J. Morris and P. A. Barker (2008). "cIAP1 and cIAP2 facilitate cancer cell  
5 survival by functioning as E3 ligases that promote RIP1 ubiquitination." *Mol Cell* **30**(6): 689-  
6 700.
- 7 Cai, Z., S. Jitkaew, J. Zhao, H. C. Chiang, S. Choksi, J. Liu, Y. Ward, L. G. Wu and Z. G. Liu  
8 (2014). "Plasma membrane translocation of trimerized MLKL protein is required for TNF-  
9 induced necroptosis." *Nat Cell Biol* **16**(1): 55-65.
- 10 Chen, X., W. Li, J. Ren, D. Huang, W. T. He, Y. Song, C. Yang, W. Li, X. Zheng, P. Chen and J.  
11 Han (2014). "Translocation of mixed lineage kinase domain-like protein to plasma  
12 membrane leads to necrotic cell death." *Cell Res* **24**(1): 105-121.
- 13 Cox, J., N. Neuhauser, A. Michalski, R. A. Scheltema, J. V. Olsen and M. Mann (2011).  
14 "Andromeda: a peptide search engine integrated into the MaxQuant environment." *J*  
15 *Proteome Res* **10**(4): 1794-1805.
- 16 Davies, K. A., C. Fitzgibbon, S. N. Young, S. E. Garnish, W. Yeung, D. Coursier, R. W.  
17 Birkinshaw, J. J. Sandow, W. I. L. Lehmann, L. Y. Liang, I. S. Lucet, J. D. Chalmers, W. M.  
18 Patrick, N. Kannan, E. J. Petrie, P. E. Czabotar and J. M. Murphy (2020). "Distinct  
19 pseudokinase domain conformations underlie divergent activation mechanisms among  
20 vertebrate MLKL orthologues." *Nat Commun* **11**(1): 3060.
- 21 Davies, K. A., M. C. Tanzer, M. D. W. Griffin, Y. F. Mok, S. N. Young, R. Qin, E. J. Petrie, P. E.  
22 Czabotar, J. Silke and J. M. Murphy (2018). "The brace helices of MLKL mediate interdomain  
23 communication and oligomerisation to regulate cell death by necroptosis." *Cell Death Differ*  
24 **25**(9): 1567-1580.
- 25 Delconte, R. B., T. B. Kolesnik, L. F. Dagley, J. Rautela, W. Shi, E. M. Putz, K. Stannard, J. G.  
26 Zhang, C. Teh, M. Firth, T. Ushiki, C. E. Andoniou, M. A. Degli-Esposti, P. P. Sharp, C. E.  
27 Sanvitale, G. Infusini, N. P. Liau, E. M. Linossi, C. J. Burns, S. Carotta, D. H. Gray, C. Seillet, D.  
28 S. Hutchinson, G. T. Belz, A. I. Webb, W. S. Alexander, S. S. Li, A. N. Bullock, J. J. Babon, M. J.  
29 Smyth, S. E. Nicholson and N. D. Huntington (2016). "CIS is a potent checkpoint in NK cell-  
30 mediated tumor immunity." *Nat Immunol* **17**(7): 816-824.
- 31 Dondelinger, Y., M. Darding, M. J. Bertrand and H. Walczak (2016). "Poly-ubiquitination in  
32 TNFR1-mediated necroptosis." *Cell Mol Life Sci* **73**(11-12): 2165-2176.

This article is protected by copyright. All rights reserved

1 Dovey, C. M., J. Diep, B. P. Clarke, A. T. Hale, D. E. McNamara, H. Guo, N. W. Brown, Jr., J. Y.  
2 Cao, C. R. Grace, P. J. Gough, J. Bertin, S. J. Dixon, D. Fiedler, E. S. Mocarski, W. J. Kaiser, T.  
3 Moldoveanu, J. D. York and J. E. Carette (2018). "MLKL Requires the Inositol Phosphate Code  
4 to Execute Necroptosis." *Mol Cell* **70**(5): 936-948 e937.  
5 Draber, P., S. Kupka, M. Reichert, H. Draberova, E. Lafont, D. de Miguel, L. Spilgies, S.  
6 Surinova, L. Taraborrelli, T. Hartwig, E. Rieser, L. Martino, K. Rittinger and H. Walczak (2015).  
7 "LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting  
8 Opposing Effects on Linear Ubiquitin in Signaling Complexes." *Cell Rep* **13**(10): 2258-2272.  
9 Fan, W., J. Guo, B. Gao, W. Zhang, L. Ling, T. Xu, C. Pan, L. Li, S. Chen, H. Wang, J. Zhang and  
10 X. Wang (2019). "Flotillin-mediated endocytosis and ALIX-syntenin-1-mediated exocytosis  
11 protect the cell membrane from damage caused by necroptosis." *Sci Signal* **12**(583).  
12 Garcia, L. R., T. Tenev, R. Newman, R. O. Haich, G. Liccardi, S. W. John, A. Annibaldi, L. Yu, M.  
13 Pardo, S. N. Young, C. Fitzgibbon, W. Fernando, N. Guppy, H. Kim, L. Y. Liang, I. S. Lucet, A.  
14 Kueh, I. Roxanis, P. Gazinska, M. Sims, T. Smyth, G. Ward, J. Bertin, A. M. Beal, B. Geddes, J.  
15 S. Choudhary, J. M. Murphy, K. Aurelia Ball, J. W. Upton and P. Meier (2021). "Ubiquitylation  
16 of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen  
17 clearance." *Nat Commun* **12**(1): 3364.  
18 Gong, Y. N., C. Guy, H. Olauson, J. U. Becker, M. Yang, P. Fitzgerald, A. Linkermann and D. R.  
19 Green (2017). "ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and  
20 Its Consequences." *Cell* **169**(2): 286-300 e216.  
21 Haas, T. L., C. H. Emmerich, B. Gerlach, A. C. Schmukle, S. M. Cordier, E. Rieser, R. Feltham, J.  
22 Vince, U. Warnken, T. Wenger, R. Koschny, D. Komander, J. Silke and H. Walczak (2009).  
23 "Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling  
24 complex and is required for TNF-mediated gene induction." *Mol Cell* **36**(5): 831-844.  
25 Haglund, K., S. Sigismund, S. Polo, I. Szymkiewicz, P. P. Di Fiore and I. Dikic (2003). "Multiple  
26 monoubiquitination of RTKs is sufficient for their endocytosis and degradation." *Nat Cell Biol*  
27 **5**(5): 461-466.  
28 Hancock, J. F., K. Cadwallader, H. Paterson and C. J. Marshall (1991). "A CAAX or a CAAL  
29 motif and a second signal are sufficient for plasma membrane targeting of ras proteins."  
30 *EMBO J* **10**(13): 4033-4039.  
31 Hildebrand, J. M., M. Kauppi, I. J. Majewski, Z. Liu, A. J. Cox, S. Miyake, E. J. Petrie, M. A. Silk,  
32 Z. Li, M. C. Tanzer, G. Brumatti, S. N. Young, C. Hall, S. E. Garnish, J. Corbin, M. D. Stutz, L. Di

This article is protected by copyright. All rights reserved

1 Rago, P. Gangatirkar, E. C. Josefsson, K. Rigbye, H. Anderton, J. A. Rickard, A. Tripaydonis, J.  
2 Sheridan, T. S. Scerri, V. E. Jackson, P. E. Czabotar, J. G. Zhang, L. Varghese, C. C. Allison, M.  
3 Pellegrini, G. M. Tannahill, E. C. Hatchell, T. A. Willson, D. Stockwell, C. A. de Graaf, J.  
4 Collinge, A. Hilton, N. Silke, S. K. Spall, D. Chau, V. Athanasopoulos, D. Metcalf, R. M. Laxer, A.  
5 G. Bassuk, B. W. Darbro, M. A. Fiatarone Singh, N. Vlahovich, D. Hughes, M. Kozlovskaja, D. B.  
6 Ascher, K. Warnatz, N. Venhoff, J. Thiel, C. Biben, S. Blum, J. Reveille, M. S. Hildebrand, C. G.  
7 Vinuesa, P. McCombe, M. A. Brown, B. T. Kile, C. McLean, M. Bahlo, S. L. Masters, H. Nakano,  
8 P. J. Ferguson, J. M. Murphy, W. S. Alexander and J. Silke (2020). "A missense mutation in  
9 the MLKL brace region promotes lethal neonatal inflammation and hematopoietic  
10 dysfunction." *Nat Commun* **11**(1): 3150.  
11 Hildebrand, J. M., M. C. Tanzer, I. S. Lucet, S. N. Young, S. K. Spall, P. Sharma, C. Pierotti, J. M.  
12 Garnier, R. C. Dobson, A. I. Webb, A. Tripaydonis, J. J. Babon, M. D. Mulcair, M. J. Scanlon, W.  
13 S. Alexander, A. F. Wilks, P. E. Czabotar, G. Lessene, J. M. Murphy and J. Silke (2014).  
14 "Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce  
15 membrane localization and necroptotic cell death." *Proc Natl Acad Sci U S A* **111**(42): 15072-  
16 15077.  
17 Hjerpe, R., F. Aillet, F. Lopitz-Otsoa, V. Lang, P. England and M. S. Rodriguez (2009).  
18 "Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding  
19 entities." *EMBO Rep* **10**(11): 1250-1258.  
20 Holler, N., R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider,  
21 B. Seed and J. Tschopp (2000). "Fas triggers an alternative, caspase-8-independent cell  
22 death pathway using the kinase RIP as effector molecule." *Nat Immunol* **1**(6): 489-495.  
23 Hospenthal, M. K., T. E. T. Mevissen and D. Komander (2015). "Deubiquitinase-based  
24 analysis of ubiquitin chain architecture using Ubiquitin Chain Restriction (UbiCRest)." *Nat*  
25 *Protoc* **10**(2): 349-361.  
26 Huang, F., X. Zeng, W. Kim, M. Balasubramani, A. Fortian, S. P. Gygi, N. A. Yates and A. Sorkin  
27 (2013). "Lysine 63-linked polyubiquitination is required for EGF receptor degradation." *Proc*  
28 *Natl Acad Sci U S A* **110**(39): 15722-15727.  
29 Ikeda, F., Y. L. Deribe, S. S. Skanland, B. Stieglitz, C. Grabbe, M. Franz-Wachtel, S. J. van Wijk,  
30 P. Goswami, V. Nagy, J. Terzic, F. Tokunaga, A. Androulidaki, T. Nakagawa, M. Pasparakis, K.  
31 Iwai, J. P. Sundberg, L. Schaefer, K. Rittinger, B. Macek and I. Dikic (2011). "SHARPIN forms a

This article is protected by copyright. All rights reserved

1 linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis." Nature  
2 **471**(7340): 637-641.

3 Jacobsen, A. V., K. N. Lowes, M. C. Tanzer, I. S. Lucet, J. M. Hildebrand, E. J. Petrie, M. F. van  
4 Delft, Z. Liu, S. A. Conos, J. G. Zhang, D. C. Huang, J. Silke, G. Lessene and J. M. Murphy  
5 (2016). "HSP90 activity is required for MLKL oligomerisation and membrane translocation  
6 and the induction of necroptotic cell death." Cell Death Dis **7**: e2051.

7 Kaczmarek, A., P. Vandenabeele and D. V. Krysko (2013). "Necroptosis: the release of  
8 damage-associated molecular patterns and its physiological relevance." Immunity **38**(2):  
9 209-223.

10 Kaiser, W. J., H. Sridharan, C. Huang, P. Mandal, J. W. Upton, P. J. Gough, C. A. Sehon, R. W.  
11 Marquis, J. Bertin and E. S. Mocarski (2013). "Toll-like receptor 3-mediated necrosis via TRIF,  
12 RIP3, and MLKL." J Biol Chem **288**(43): 31268-31279.

13 Kedzierski, L., M. D. Tate, A. C. Hsu, T. B. Kolesnik, E. M. Linossi, L. Dagley, Z. Dong, S.  
14 Freeman, G. Infusini, M. R. Starkey, N. L. Bird, S. M. Chatfield, J. J. Babon, N. Huntington, G.  
15 Belz, A. Webb, P. A. Wark, N. A. Nicola, J. Xu, K. Kedzierska, P. M. Hansbro and S. E.  
16 Nicholson (2017). "Suppressor of Cytokine Signaling (SOCS)5 ameliorates influenza infection  
17 via inhibition of EGFR signaling." Elife **6**.

18 Keusekotten, K., P. R. Elliott, L. Glockner, B. K. Fiil, R. B. Damgaard, Y. Kulathu, T. Wauer, M.  
19 K. Hospenthal, M. Gyrd-Hansen, D. Krappmann, K. Hofmann and D. Komander (2013).  
20 "OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin."  
21 Cell **153**(6): 1312-1326.

22 Lacey, D., P. Hickey, B. D. Arhatari, L. A. O'Reilly, L. Rohrbeck, H. Kiriazis, X. J. Du and P.  
23 Bouillet (2015). "Spontaneous retrotransposon insertion into TNF 3'UTR causes heart valve  
24 disease and chronic polyarthritis." Proc Natl Acad Sci U S A **112**(31): 9698-9703.

25 Lawlor, K. E., N. Khan, A. Mildenhall, M. Gerlic, B. A. Croker, A. A. D'Cruz, C. Hall, S. Kaur  
26 Spall, H. Anderton, S. L. Masters, M. Rashidi, I. P. Wicks, W. S. Alexander, Y. Mitsuuchi, C. A.  
27 Benetatos, S. M. Condon, W. W. Wong, J. Silke, D. L. Vaux and J. E. Vince (2015). "RIPK3  
28 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL." Nat  
29 Commun **6**: 6282.

30 Li, D., T. Xu, Y. Cao, H. Wang, L. Li, S. Chen, X. Wang and Z. Shen (2015). "A cytosolic heat  
31 shock protein 90 and cochaperone CDC37 complex is required for RIP3 activation during  
32 necroptosis." Proc Natl Acad Sci U S A **112**(16): 5017-5022.

This article is protected by copyright. All rights reserved

1 Liu, S., H. Liu, A. Johnston, S. Hanna-Addams, E. Reynoso, Y. Xiang and Z. Wang (2017).  
2 "MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis." Proc  
3 Natl Acad Sci U S A **114**(36): E7450-E7459.  
4 Liu, Z., J. Silke and J. M. Hildebrand (2018). "Methods for Studying TNF-Mediated  
5 Necroptosis in Cultured Cells." Methods Mol Biol **1857**: 53-61.  
6 Menon, M. B. and M. Gaestel (2018). "MK2-TNF-Signaling Comes Full Circle." Trends  
7 Biochem Sci **43**(3): 170-179.  
8 Morrow, M. E., M. T. Morgan, M. Clerici, K. Growkova, M. Yan, D. Komander, T. K. Sixma, M.  
9 Simicek and C. Wolberger (2018). "Active site alanine mutations convert deubiquitinases  
10 into high-affinity ubiquitin-binding proteins." EMBO Rep **19**(10).  
11 Mosesson, Y. and Y. Yarden (2006). "Monoubiquitylation: a recurrent theme in membrane  
12 protein transport." Isr Med Assoc J **8**(4): 233-237.  
13 Moujalled, D. M., W. D. Cook, J. M. Murphy and D. L. Vaux (2014). "Necroptosis induced by  
14 RIPK3 requires MLKL but not Drp1." Cell Death Dis **5**: e1086.  
15 Murai, S., Y. Yamaguchi, Y. Shirasaki, M. Yamagishi, R. Shindo, J. M. Hildebrand, R. Miura, O.  
16 Nakabayashi, M. Totsuka, T. Tomida, S. Adachi-Akahane, S. Uemura, J. Silke, H. Yagita, M.  
17 Miura and H. Nakano (2018). "A FRET biosensor for necroptosis uncovers two different  
18 modes of the release of DAMPs." Nat Commun **9**(1): 4457.  
19 Murphy, J. M., P. E. Czabotar, J. M. Hildebrand, I. S. Lucet, J. G. Zhang, S. Alvarez-Diaz, R.  
20 Lewis, N. Lalaoui, D. Metcalf, A. I. Webb, S. N. Young, L. N. Varghese, G. M. Tannahill, E. C.  
21 Hatchell, I. J. Majewski, T. Okamoto, R. C. Dobson, D. J. Hilton, J. J. Babon, N. A. Nicola, A.  
22 Strasser, J. Silke and W. S. Alexander (2013). "The pseudokinase MLKL mediates necroptosis  
23 via a molecular switch mechanism." Immunity **39**(3): 443-453.  
24 Oh, E., D. Akopian and M. Rape (2018). "Principles of Ubiquitin-Dependent Signaling." Annu  
25 Rev Cell Dev Biol **34**: 137-162.  
26 Onizawa, M., S. Oshima, U. Schulze-Topphoff, J. A. Oses-Prieto, T. Lu, R. Tavares, T.  
27 Prodhomme, B. Duong, M. I. Whang, R. Advincula, A. Agelidis, J. Barrera, H. Wu, A.  
28 Burlingame, B. A. Malynn, S. S. Zamvil and A. Ma (2015). "The ubiquitin-modifying enzyme  
29 A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis." Nat  
30 Immunol **16**(6): 618-627.

This article is protected by copyright. All rights reserved

1 Orozco, S., N. Yatim, M. R. Werner, H. Tran, S. Y. Gunja, S. W. Tait, M. L. Albert, D. R. Green  
2 and A. Oberst (2014). "RIPK1 both positively and negatively regulates RIPK3 oligomerization  
3 and necroptosis." *Cell Death Differ* **21**(10): 1511-1521.

4 Perez-Riverol, Y., A. Csordas, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. J. Kundu, A.  
5 Inuganti, J. Griss, G. Mayer, M. Eisenacher, E. Perez, J. Uszkoreit, J. Pfeuffer, T. Sachsenberg,  
6 S. Yilmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A. F. Jarnuczak, T. Ternent, A. Brazma and J.  
7 A. Vizcaino (2019). "The PRIDE database and related tools and resources in 2019: improving  
8 support for quantification data." *Nucleic Acids Res* **47**(D1): D442-D450.

9 Petersen, S. L., T. T. Chen, D. A. Lawrence, S. A. Marsters, F. Gonzalez and A. Ashkenazi  
10 (2015). "TRAF2 is a biologically important necroptosis suppressor." *Cell Death Differ* **22**(11):  
11 1846-1857.

12 Petrie, E. J., R. W. Birkinshaw, A. Koide, E. Denbaum, J. M. Hildebrand, S. E. Garnish, K. A.  
13 Davies, J. J. Sandow, A. L. Samson, X. Gavin, C. Fitzgibbon, S. N. Young, P. J. Hennessy, P. P. C.  
14 Smith, A. I. Webb, P. E. Czabotar, S. Koide and J. M. Murphy (2020). "Identification of MLKL  
15 membrane translocation as a checkpoint in necroptotic cell death using Monobodies." *Proc*  
16 *Natl Acad Sci U S A* **117**(15): 8468-8475.

17 Petrie, E. J., P. E. Czabotar and J. M. Murphy (2019). "The Structural Basis of Necroptotic Cell  
18 Death Signaling." *Trends Biochem Sci* **44**(1): 53-63.

19 Petrie, E. J., J. J. Sandow, A. V. Jacobsen, B. J. Smith, M. D. W. Griffin, I. S. Lucet, W. Dai, S. N.  
20 Young, M. C. Tanzer, A. Wardak, L. Y. Liang, A. D. Cowan, J. M. Hildebrand, W. J. A. Kersten,  
21 G. Lessene, J. Silke, P. E. Czabotar, A. I. Webb and J. M. Murphy (2018). "Conformational  
22 switching of the pseudokinase domain promotes human MLKL tetramerization and cell  
23 death by necroptosis." *Nat Commun* **9**(1): 2422.

24 Petrie, E. J., J. J. Sandow, W. I. L. Lehmann, L. Y. Liang, D. Coursier, S. N. Young, W. J. A.  
25 Kersten, C. Fitzgibbon, A. L. Samson, A. V. Jacobsen, K. N. Lowes, A. E. Au, H. Jousset Sabroux,  
26 N. Lalaoui, A. I. Webb, G. Lessene, G. Manning, I. S. Lucet and J. M. Murphy (2019). "Viral  
27 MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3." *Cell Rep*  
28 **28**(13): 3309-3319 e3305.

29 Petroski, M. D. and R. J. Deshaies (2003). "Context of multiubiquitin chain attachment  
30 influences the rate of Sic1 degradation." *Mol Cell* **11**(6): 1435-1444.

31 Samson, A. L., Y. Zhang, N. D. Geoghegan, X. J. Gavin, K. A. Davies, M. J. Mlodzianoski, L. W.  
32 Whitehead, D. Frank, S. E. Garnish, C. Fitzgibbon, A. Hempel, S. N. Young, A. V. Jacobsen, W.

This article is protected by copyright. All rights reserved

1 Cawthorne, E. J. Petrie, M. C. Faux, K. Shield-Artin, N. Lalaoui, J. M. Hildebrand, J. Silke, K. L.  
2 Rogers, G. Lessene, E. D. Hawkins and J. M. Murphy (2020). "MLKL trafficking and  
3 accumulation at the plasma membrane control the kinetics and threshold for necroptosis."  
4 Nat Commun **11**(1): 3151.

5 Sapmaz, A., I. Berlin, E. Bos, R. H. Wijdeven, H. Janssen, R. Konietzny, J. J. Akkermans, A. E.  
6 Erson-Bensan, R. I. Koning, B. M. Kessler, J. Neefjes and H. Ovaa (2019). "USP32 regulates  
7 late endosomal transport and recycling through deubiquitylation of Rab7." Nat Commun  
8 **10**(1): 1454.

9 Schagger, H. and G. von Jagow (1991). "Blue native electrophoresis for isolation of  
10 membrane protein complexes in enzymatically active form." Anal Biochem **199**(2): 223-231.

11 Segawa, K. and S. Nagata (2015). "An Apoptotic 'Eat Me' Signal: Phosphatidylserine  
12 Exposure." Trends Cell Biol **25**(11): 639-650.

13 Stafford, C. A., K. E. Lawlor, V. J. Heim, A. Bankovacki, J. P. Bernardini, J. Silke and U. Nachbur  
14 (2018). "IAPs Regulate Distinct Innate Immune Pathways to Co-ordinate the Response to  
15 Bacterial Peptidoglycans." Cell Rep **22**(6): 1496-1508.

16 Sun, X., J. Yin, M. A. Starovasnik, W. J. Fairbrother and V. M. Dixit (2002). "Identification of a  
17 novel homotypic interaction motif required for the phosphorylation of receptor-interacting  
18 protein (RIP) by RIP3." J Biol Chem **277**(11): 9505-9511.

19 Swatek, K. N. and D. Komander (2016). "Ubiquitin modifications." Cell Res **26**(4): 399-422.

20 Tanzer, M. C., I. Matti, J. M. Hildebrand, S. N. Young, A. Wardak, A. Tripaydonis, E. J. Petrie,  
21 A. L. Mildenhall, D. L. Vaux, J. E. Vince, P. E. Czabotar, J. Silke and J. M. Murphy (2016).  
22 "Evolutionary divergence of the necroptosis effector MLKL." Cell Death Differ **23**(7): 1185-  
23 1197.

24 Tanzer, M. C., A. Tripaydonis, A. I. Webb, S. N. Young, L. N. Varghese, C. Hall, W. S. Alexander,  
25 J. M. Hildebrand, J. Silke and J. M. Murphy (2015). "Necroptosis signalling is tuned by  
26 phosphorylation of MLKL residues outside the pseudokinase domain activation loop."  
27 Biochem J **471**(2): 255-265.

28 Tokunaga, F., S. Sakata, Y. Saeki, Y. Satomi, T. Kirisako, K. Kamei, T. Nakagawa, M. Kato, S.  
29 Murata, S. Yamaoka, M. Yamamoto, S. Akira, T. Takao, K. Tanaka and K. Iwai (2009).  
30 "Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation." Nat Cell Biol  
31 **11**(2): 123-132.

This article is protected by copyright. All rights reserved

1 Vanden Berghe, T., W. J. Kaiser, M. J. Bertrand and P. Vandenabeele (2015). "Molecular  
2 crosstalk between apoptosis, necroptosis, and survival signaling." Mol Cell Oncol **2**(4):  
3 e975093.

4 Vandenabeele, P., F. Riquet and B. Cappe (2017). "Necroptosis: (Last) Message in a Bubble."  
5 Immunity **47**(1): 1-3.

6 Wang, H., L. Sun, L. Su, J. Rizo, L. Liu, L. F. Wang, F. S. Wang and X. Wang (2014). "Mixed  
7 lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon  
8 phosphorylation by RIP3." Mol Cell **54**(1): 133-146.

9 Wang, Z., H. Jiang, S. Chen, F. Du and X. Wang (2012). "The mitochondrial phosphatase  
10 PGAM5 functions at the convergence point of multiple necrotic death pathways." Cell  
11 **148**(1-2): 228-243.

12 Weber, K., R. Roelandt, I. Bruggeman, Y. Estornes and P. Vandenabeele (2018). "Nuclear  
13 RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis." Commun  
14 Biol **1**: 6.

15 Wilkinson, K. D., V. L. Tashayev, L. B. O'Connor, C. N. Larsen, E. Kasperek and C. M. Pickart  
16 (1995). "Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role  
17 of isopeptidase T." Biochemistry **34**(44): 14535-14546.

18 Wisniewski, J. R., A. Zougman, N. Nagaraj and M. Mann (2009). "Universal sample  
19 preparation method for proteome analysis." Nat Methods **6**(5): 359-362.

20 Wright, L. P. and M. R. Philips (2006). "Thematic review series: lipid posttranslational  
21 modifications. CAAX modification and membrane targeting of Ras." J Lipid Res **47**(5): 883-  
22 891.

23 Wu, G., G. Xu, B. A. Schulman, P. D. Jeffrey, J. W. Harper and N. P. Pavletich (2003).  
24 "Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine  
25 specificity of the SCF(beta-TrCP1) ubiquitin ligase." Mol Cell **11**(6): 1445-1456.

26 Wu, X. N., Z. H. Yang, X. K. Wang, Y. Zhang, H. Wan, Y. Song, X. Chen, J. Shao and J. Han  
27 (2014). "Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating  
28 necroptosis." Cell Death Differ **21**(11): 1709-1720.

29 Ye, Y., M. Akutsu, F. Reyes-Turcu, R. I. Enchev, K. D. Wilkinson and D. Komander (2011).  
30 "Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21." EMBO  
31 Rep **12**(4): 350-357.

This article is protected by copyright. All rights reserved

1 Ye, Y., G. Blaser, M. H. Horrocks, M. J. Ruedas-Rama, S. Ibrahim, A. A. Zhukov, A. Orte, D.  
 2 Klenerman, S. E. Jackson and D. Komander (2012). "Ubiquitin chain conformation regulates  
 3 recognition and activity of interacting proteins." *Nature* **492**(7428): 266-270.  
 4 Yoon, S., K. Bogdanov, A. Kovalenko and D. Wallach (2016). "Necroptosis is preceded by  
 5 nuclear translocation of the signaling proteins that induce it." *Cell Death Differ* **23**(2): 253-  
 6 260.  
 7 Yoon, S., A. Kovalenko, K. Bogdanov and D. Wallach (2017). "MLKL, the Protein that  
 8 Mediates Necroptosis, Also Regulates Endosomal Trafficking and Extracellular Vesicle  
 9 Generation." *Immunity* **47**(1): 51-65 e57.  
 10 Zargarian, S., I. Shlomovitz, Z. Erlich, A. Hourizadeh, Y. Ofir-Birin, B. A. Croker, N. Regev-  
 11 Rudzki, L. Edry-Botzer and M. Gerlic (2017). "Phosphatidylserine externalization,  
 12 "necroptotic bodies" release, and phagocytosis during necroptosis." *PLoS Biol* **15**(6):  
 13 e2002711.

#### 16 **Figure legends**

18 Abbreviations: Untreated (UT), TNF (T), Smac-mimetics Compound A (S), IDN-6556 (I), Q-  
 19 VD-OPh (Q), whole cell lysate (WCL), GST-UBA pull down fractions (UBA-PD), cytosolic  
 20 fraction (C), crude membrane fraction (M), wildtype (WT), C221R (CR), Propidium Iodide  
 21 (PI), Necrostatin-1 (Nec-1), ubiquitin (Ub) and others as indicated elsewhere. TS, SI, TSI and  
 22 TSQ are used in combination, as apoptotic or necroptotic stimuli.

Commented [ZL1]: Done

#### 24 **Figure 1. MLKL undergoes ubiquitylation during necroptosis.**

26 A WT MDFs were treated  $\pm$  TSI individually or in combination for 3 hrs. Whole cell lysates  
 27 (WCL) and UBA-pull down (UBA-PD) fractions were analysed by Western blot and  
 28 probed with antibodies as indicated. Representative of three independent experiments.  
 29 Samples of UBA-pull down in following figures were analysed in the same way unless  
 30 otherwise indicated.  
 31 B WT, *Ripk3*<sup>-/-</sup>, *Mkl1*<sup>-/-</sup>, *Tnfr1*<sup>-/-</sup> and *Traf2*<sup>-/-</sup> MDFs were untreated (UT) or treated with TSI  
 32 for 3 hrs. Nec-1 and GSK872 were added to inhibit RIPK1 and RIPK3 kinase activities  
 33 respectively.

This article is protected by copyright. All rights reserved

- 1 C WT and *Tnf*<sup>-/-</sup> BMDMs were treated ± death ligands including TNF (T), LPS (L), Fas  
2 ligand (F) and Poly I:C (P) in addition to S and I for 3 hrs.  
3 D WT HT29 cells were untreated (UT) or treated with TSI for 16 hrs.  
4 E RIPK3-gyrase were inducibly expressed in *Ripk3*<sup>-/-</sup> MDFs by doxycycline (dox) for 5 hrs,  
5 and cells were then treated ± combination of TSI, or coumermycin (coum) for 3 hrs.  
6

7 **Figure 2. MLKL is mono-ubiquitylated at multiple sites.**

- 8  
9 A Deubiquitylating enzymes (DUBs) and their ubiquitin substrates. Less efficiently cleaved  
10 substrates are indicated in brackets.  
11 B UBA-pull down from WT MDFs treated with TSI for 3 hrs were subjected to the DUBs  
12 shown in (A). Beads eluates were analysed by Western blot and probed with antibodies as  
13 indicated. Representative of three independent experiments.  
14 C 1.4 mL cleared cell lysate from 4 x 10<sup>6</sup> TSI-treated WT MDFs was split into three parts of  
15 the indicated volume, followed by UBA-pull down and DUB incubation. Bead eluates  
16 were analysed by Western blot and probed with the indicated antibodies. Representative of  
17 three independent experiments.  
18

19 **Figure 3. MLKL ubiquitylation accumulates in the crude membrane fraction and can  
20 be digested by USP21 located on biological membranes.**

- 21  
22 A WT MDFs were treated with TSI for indicated time. Cells were fractionated into cytosol  
23 and crude membrane, followed by UBA-pull down. All fractions were analysed by  
24 Western blot and probed with antibodies as indicated. Representative of three independent  
25 experiments.  
26 B WT USP21-CaaX and USP21<sup>C221R</sup>-CaaX (CR) were inducibly expressed in WT MDFs by  
27 doxycycline for 5 hrs. Ubiquitylated proteins were enriched followed by TSI stimulation  
28 and cellular fractionation. All fractions were analysed by Western blot and probed with  
29 antibodies as indicated. Representative of three independent experiments.  
30

31 **Figure 4. MLKL oligomerization drives its necroptosis specific ubiquitylation.**

- 32  
33 A WT and R105AD106A mutant MLKL were inducibly expressed in *Mkl1*<sup>-/-</sup> MDFs by  
34 doxycycline, at the same time cells were untreated (UT) or treated with TSQ for 6 hrs.

This article is protected by copyright. All rights reserved

1 Cells were fractionated into cytosol (C) and crude membrane (M). Fractions were  
2 analysed by BN- or SDS-PAGE, Western blot and probed with the indicated antibodies.  
3 Representative of three independent experiments.

4 B Cell lysates from (A) were subjected to UBA-pull down and analysed as described above.

5 C WT, Q343A and S345D mutant MLKL were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs by  
6 doxycycline, at the same time cells were treated ± TSQ for 16 hrs, followed by UBA-  
7 pulldown. Representative of three independent experiments.

8 D WT and Q343A mutant MLKL were inducibly expressed in *Ripk3<sup>-/-</sup>Mkl<sup>-/-</sup>* MDFs by  
9 doxycycline, at the same time cells were treated ± TSQ for 16 hrs, followed by UBA-  
10 pulldown. Representative of three independent experiments.

11 E HT29 cells were stimulated with TSI, ± NSA (500 nM), or left untreated (UT) for 16 hrs,  
12 followed by cellular fractionation. Fractions were analysed by BN- or SDS-PAGE,  
13 Western blot and probed with the indicated antibodies. Representative of three  
14 independent experiments.

15 F Cell lysates from (E) were subjected to UBA-pulldown and analysed as described above.

16 **Figure 5. MLKL-ubiquitylation does not lead to cell death, but correlates with the**  
17 **turnover of activated MLKL.**

18

19 A WT and E109AE110A mutant MLKL were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs by  
20 doxycycline, cells were untreated or treated with TSQ for 6 hrs (please note that the same  
21 WT control was used in Fig. EV3A). Cell death was measured by PI staining based on  
22 flow cytometry. Data are plotted as mean ± SEM of three independent experiments.

23 B Cellular fractions from (A) were analysed by Western blot from BN-PAGE or SDS-PAGE  
24 using antibodies as indicated. The same WT control was used in Fig. 4A. Representative  
25 of three independent experiments.

26 C Cell lysates from (A) were subjected to UBA-pull down and analysed as described above.

27 D N-FLAG MLKL were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs by doxycycline overnight, and  
28 cells were treated with TSI for indicated time, followed by UBA-pull down.  
29 Representative of three independent experiments.

30 E N-FLAG MLKL were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs by doxycycline for 16 hrs.  
31 Cells were stimulated ± TSI for 3 hrs after withdrawal of doxycycline. Then TSI medium  
32 was removed and replaced to medium containing inhibitors Bafilomycin A1 (BAF),  
33 PS341 (PS) or left untreated (UT). IDN-6556 was added to all conditions to block

This article is protected by copyright. All rights reserved

1 apoptosis. Cells were collected 0, 2, 4, 6 hrs after medium replacement, followed by UBA-  
2 pull down. Representative of three independent experiments.

3

4 **Figure 6. Simultaneous arginine replacement of 4 ubiquitylation sites on the mMLKL**  
5 **4HB domain does not prevent necroptosis-induced ubiquitylation.**

6

7 A Cartoon of the N-terminal region (residues 1-180) of mouse MLKL (PDB accession  
8 4BTF;(Murphy, Czabotar et al. 2013)) showing the four lysine residues identified from  
9 MS analysis as yellow sticks.

10 B WT and 4KR mutant MLKL were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs by doxycycline for  
11 6 hrs and cells were untreated (UT) or treated with TSI, followed by UBA-pull down.  
12 Representative of three independent experiments.

13

14 **Figure 7. MLKL ubiquitylation antagonises necroptosis.**

15

16 A Schematic of the MLKL-USP21 and USP21 catalytic dead mutant proteins.

17 B Mouse MLKL-USP21 and MLKL-USP21<sup>C221R</sup> were inducibly expressed in *Mkl<sup>-/-</sup>* MDFs  
18 by doxycycline (10 ng/mL) for 6 hrs with addition of a necroptotic stimulus (TSI) for the  
19 indicated time, followed by UBA-pulldown. Non-specific band is indicated with “\*” in the  
20 blot of RIPK3. Representative of three independent experiments.

21 C *Mkl<sup>-/-</sup>* MDFs and *Ripk3<sup>-/-</sup>Mkl<sup>-/-</sup>* MDFs stably transfected with constructs encoding MLKL,  
22 USP21, USP21<sup>C221R</sup>, MLKL-USP21 and MLKL-USP21<sup>C221R</sup> were treated with  
23 doxycycline, TSI or in combination. Propidium iodide positive cells were quantified in  
24 real time by IncuCyte live cell imaging. Data are plotted as mean ± SEM of three  
25 independent experiments.

26 D *MLKL<sup>-/-</sup>* HT29 cells stably transfected with constructs encoding human MLKL-USP21 and  
27 MLKL-USP21<sup>C221R</sup>, were treated with doxycycline, NSA (1 μM), TSI or combinations  
28 thereof (added simultaneously). Sytox Green positive cells were quantified in real time by  
29 live cell imaging. Data are plotted as mean ± SEM of six independent experiments. (A red  
30 dashed line is shown to highlight the delay in death kinetics upon treatment with NSA).

31 E Human MLKL-USP21 and MLKL-USP21<sup>C221R</sup> were inducibly expressed in *MLKL<sup>-/-</sup>*  
32 HT29 cells by doxycycline (10 ng/mL) for 16 hrs, TSI was added for the indicated times

Commented [HC2]: Please define the number and the nature, i.e. biological or technical, of the replicates in the representative experiment. Please define the error bars, SD.

Commented [HC3]: Please define the number and the nature, i.e. biological or technical, of the replicates in the representative experiment. Please define the error bars, SD.

1 but all samples were collected 25 hrs post-induction, followed by UBA-pulldown.  
2 Representative of three independent experiments.

#### 3 4 **Expanded view figure legends**

#### 5 6 **Expanded View Figure 1. Cell death time course of MDFs and HT29 cells following** 7 **necroptotic stimulation.**

8  
9 (A, B) MDFs (A) and HT29 (B) cells were treated with TSI. Cell death was measured by PI  
10 staining and flow cytometry. Data are plotted as mean  $\pm$  SEM of at least three independent  
11 experiments.

#### 12 13 **Expanded View Figure 2. USP21-CaaX expression does not alter the kinetics of TNF** 14 **induced apoptosis or necroptosis in MDFs.**

15  
16 WT USP21, USP21-CaaX and USP21<sup>C221R</sup>-CaaX were inducibly expressed in WT MDFs by  
17 doxycycline. TS and Nec-1s were used to control for apoptotic signalling and TSI was used  
18 to  
19 trigger necroptotic signalling. Sytox Green positive cells were quantified in real time by live  
20 cell imaging. Data are plotted as mean  $\pm$  SEM of two independent experiments.

Commented [HC4]: Please also remove the 'A' label from the figure.

Commented [ZL5]: Yes it should be Nec-1s, thanks

Commented [ZL6]: resolved

#### 21 22 **Expanded View Figure 3. MLKL oligomerization drives its necroptosis specific** 23 **ubiquitylation**

24  
25 A Cell death of samples from Fig. 4A were measured by PI staining based on flow cytometry.  
26 Data are plotted as mean  $\pm$  SEM of three independent experiments.  
27 B Cell death of samples from Fig. 4C, D were analysed as in (A).

#### 28 29 **Expanded View Figure 4. N-FLAG MLKL behaves like WT MLKL but does not induce** 30 **cell death following necroptotic stimulation.**

31  
32 A WT MLKL and N-FLAG MLKL were inducibly expressed in *Mkl1*<sup>-/-</sup> MDFs by  
33 doxycycline for 12 hrs and cells were treated with TSI or TSQ. TS treatment controlled

1 that the response to TS was normal. Cell death was measured by PI staining based on flow  
2 cytometry. Data are plotted as mean  $\pm$  SEM of three independent experiments.

3 B WT MLKL and N-FLAG MLKL were inducibly expressed in *Mlkl*<sup>-/-</sup> MDFs by  
4 doxycycline for 6 hrs, cells were untreated (UT) or treated with TSQ. Cellular fractions  
5 were analysed by Western blot from BN-PAGE or SDS-PAGE using antibodies as  
6 indicated. Representative of three independent experiments.

7  
8 **Expanded View Figure 5. Simultaneous arginine replacement of 4 ubiquitylation sites**  
9 **on the mouse MLKL 4HB domain does not prevent necroptosis-induced ubiquitylation.**

10  
11 A MS spectra were manually validated to confirm the identification of four Gly-Gly sites on  
12 activated MLKL.

13 B Alignment of mouse and human MLKL N-terminal domain. Positively charged residues  
14 are labelled in blue and negatively charged residues are labelled in pink.

15 C WT and 4KR mutant MLKL were inducibly expressed in *Mlkl*<sup>-/-</sup> MDFs by doxycycline (at  
16 the indicated concentrations) and cells were treated  $\pm$  TSI (added simultaneously) for 4  
17 hrs. Sytox Green positive cells were quantified in real time by IncuCyte S3 live cell  
18 imaging. Data are plotted as mean  $\pm$  SEM of three independent experiments.

Commented [ZL7]: resolved

19  
20 **Expanded View Figure 6. MLKL ubiquitylation antagonises necroptosis.**

21  
22 A Mouse MLKL, USP21, USP21<sup>C221R</sup>, MLKL-USP21 and MLKL-USP21<sup>C221R</sup> fusions were  
23 inducibly expressed in *Mlkl*<sup>-/-</sup> MDFs and *Ripk3*<sup>-/-</sup>*Mlkl*<sup>-/-</sup> MDFs as indicated, following  
24 doxycycline addition (20 ng/mL) for 6 hours  $\pm$  TSI. Representative of 2 independent  
25 experiments.

Commented [ZL8]: resolved


26 B *MLKL*<sup>-/-</sup> HT29 cells stably transfected with doxycycline inducible constructs encoding  
27 human USP21 and human USP21<sup>C221R</sup> were treated with doxycycline, NSA (1  $\mu$ M), TSI  
28 or combinations thereof (added simultaneously). Sytox Green positive cells were  
29 quantified in real time by live cell imaging. Representative of 2 independent experiments.

30 C Mouse MLKL-USP21 and MLKL-USP21<sup>C221R</sup> fusions were inducibly expressed in *Mlkl*<sup>-/-</sup>  
31 MDFs by doxycycline (10 ng/mL) for 8 hrs with addition of a necroptotic stimulus (TSI)  
32 for 3hrs, followed by UBA-pulldown and USP21 digestion. Antibody (D6E3G, Cell

1 Signaling Technology) was used here to detect MLKL phosphorylation. Representative of  
2 2 independent experiments.


3 D *MLKL*<sup>-/-</sup> HT29 cells were stably transfected with indicated doxycycline inducible *MLKL*  
4 alleles (phospho-mimetic human MLKL mutant T357E/S358E indicated as MLKL<sup>TSEE</sup>)  
5 and treated with doxycycline (100 ng/mL) ± TSI (added simultaneously). A residue band  
6 from MLKL blot is indicated by “\*” in RIPK3 blot due to reprobng. Representative of 3  
7 independent experiments.

Expanded View Figure 1. Cell death time course of MDFs and HT29 cells following necroptotic stimulation




**Expanded View Figure 2. USP21-CaaX expression does not alter the kinetics of TNF induced apoptosis or necroptosis in MDFs**


WT MDF






Expanded View Figure 3. MLKL oligomerization drives its necroptosis specific ubiquitylation




Expanded View Figure 4. N-FLAG MLKL behaves like WT MLKL but does not induce cell death following necroptotic stimulation




**Expanded View Figure 5. Simultaneous arginine replacement of 4 ubiquitylation sites on the mouse MLKL 4HB domain does not prevent necroptosis-induced ubiquitylation**




Expanded View Figure 6. MLKL ubiquitylation antagonises necroptosis





**Figure 1. MLKL undergoes ubiquitylation during necroptosis**



**Figure 2. MLKL is mono-ubiquitylated at multiple sites**


This article is protected by copyright. All rights reserved

**Figure 3. MLKL ubiquitylation accumulates in crude membranes and can be digested by USP21 located on biological membranes.**




This article is protected by copyright. All rights reserved

**Figure 4. MLKL oligomerization drives its necroptosis specific ubiquitylation**



This article is protected by copyright. All rights reserved.

**Figure 5. MLKL ubiquitylation does not lead to cell death, but correlates with the turnover of activated MLKL**



**Figure 6. Simultaneous arginine replacement of 4 ubiquitylation sites on the mMLKL 4HB domain does not prevent necroptosis-induced ubiquitylation**




Figure 7. MLKL ubiquitylation antagonises necroptosis

